Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Head & Neck 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 3Cisplatin 3trametinib 2selpercatinib 2larotrectinib 2entrectinib 2dabrafenib 2Carboplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1toripalimab 1sapanisertib 1repotrectinib 1relatlimab 1pralsetinib 1pertuzumab 1penpulimab 1palbociclib 1osimertinib 1omipalisib 1ipatasertib 1erdafitinib 1defactinib 1copanlisib 1capivasertib 1cabozantinib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Cetuximab × Head & Neck × Clear all
NCT02358031 2025-07-18

MK-3475-048

Merck Sharp & Dohme LLC

Phase 3 Completed
882 enrolled 50 charts 1 FDA
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡